Expanded Access Policy

Terremoto Biosciences, Inc. is a clinical-stage biotechnology company creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy designed to deliver superior therapeutic benefit to patients.

Expanded access programs, sometimes referred to as compassionate use or pre-approval access, are regulatory pathways that may permit the use of an investigational new drug outside of a clinical trial for patients with serious or immediately life-threatening conditions when no comparable or satisfactory alternative therapies are available. Such access is typically considered when sufficient clinical data exists to support a favorable benefit-risk assessment.

Currently, Terremoto does not offer expanded access as our investigational drugs are undergoing evaluation in early clinical trials to optimize the dosing regimen and better understand safety and tolerability. At this early stage of development, there are insufficient data to support expanded access.

Terremoto may revise this policy at any time.

If you have any questions about this policy, please contact us at 888-682-1551 or clinicaltrials@terremotobio.com. To learn more about Terremoto’s clinical trials, please visit clinicaltrials.gov.